The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical (Q44744702)
Jump to navigation
Jump to search
scientific article published in February 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical |
scientific article published in February 2004 |
Statements
1 reference
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical (English)
1 reference
1 reference
de Wit R
1 reference
Herrstedt J
1 reference
Carides AD
1 reference
Guoguang-Ma J
1 reference
Elmer M
1 reference
Schmidt C
1 reference
Evans JK
1 reference
Horgan KJ
1 reference
1 February 2004
1 reference
1 reference
Identifiers
1 reference